Topics

Circassia sets platform for strong growth in 2019 after period of consolidation

05:41 EDT 1 May 2019 | Proactive Investors

Steve Harris, chief executive of Circassia Pharmaceuticals PLC (LON:CIR), talks Proactive London's Andrew Scott through the group's 2018 results and the first quarter of this year.

Circassia's taken full commercial control of Tudorza, a treatment for chronic obstructive pulmonary disease (COPD), while its sales of its asthma product NIOX continued to grow.

They've also added AirNOvent, a late-stage nitric oxide candidate, to its pipeline, which, when approved, should aid the sales effort.

Original Article: Circassia sets platform for strong growth in 2019 after period of consolidation

NEXT ARTICLE

More From BioPortfolio on "Circassia sets platform for strong growth in 2019 after period of consolidation"

Quick Search

Relevant Topics

COPD (chronic obstructive pulmonary disease)
COPD (chronic obstructive pulmonary disease) is used for a number of conditions including chronic bronchitis and emphysema, which all  lead to the airways in the lungs becoming damaged and thus narrower,  making inhalation and exhalation harder...

Respiratory
Asthma COPD Cystic Fibrosis Pneumonia Pulmonary Medicine Respiratory Respiratory tract infections (RTIs) are any infection of the sinuses, throat, airways or lungs.  They're usually caused by viruses, but they can also ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...